Hopfner Robert Lorne's Form 4 filing
Inozyme Pharma, Inc. (INZY) · filed May 15, 2023
- Accession no.
- 0001209191-23-029521
- Filed
- May 15, 2023
- Trade date
- May 11-12, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $2.85M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hopfner Robert LorneCIK 0001551966 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 11, 2023 | Common Stock | PPurchaseAcquired | +219,230 | $6.48 | +$1,420,610.4 | 3,432,816 | Indirect | |
| May 12, 2023 | Common Stock | PPurchaseAcquired | +228,702 | $6.25 | +$1,429,387.5 | 3,661,518 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.